Eurofins BPT Italy expands efficacy testing capacity and capabilities against viruses

Michele Cavalleri, Business Unit Manager Virus Testing Italy, MicheleCavalleri@eurofins.com

During the SARS-CoV-2 pandemic, market demand for testing the virucidal efficacy of hand hygiene products, surface sanitizers and disinfectants as well as articles treated with permanent antiviral coatings against coronaviruses, reached an unprecedented historical peak.

The effects of the COVID-19 pandemic can still be felt today, with many healthcare institutions paying significant attention to emerging and re-emerging viral pathogens, in order to preempt and be prepared for future public health challenges.

Considering this market need, Eurofins BioPharma Product Testing Italy has increased its testing capacity with a new dedicated laboratory area, and has continued developing its viral library with new viral models (e.g., respiratory viruses such as influenza viruses H1N1 and H3N2, or RSV) in order to support customers to test for both seasonal epidemic events and new emerging viruses, with validated and internationally recognised test methods.

Testing capability is not just limited to a large viral library but also includes different product typologies, such as:

• Liquid products for disinfection of hands, surfaces and surgical instruments
• Nebulised airborne products for disinfection of hospital rooms, canteens, public spaces
• UV devices used to mitigate viruses on surfaces (e.g. reusable PPEs, public toilets)
• Treated articles (porous and non-porous articles) with antiviral properties.

Eurofins BioPharma Product Testing Italy provides a broad spectrum of antiviral and virucidal tests, and contributes to the development of new and effective means to support the safety of products and people across the globe. For further information, contact us at InfoBiocides@eurofins.com or visit: www.eurofins.it/virucidal-efficacy-testing/